Deutsche Heilpraktiker-Zeitschrift 2023; 18(03): 22-25
DOI: 10.1055/a-2073-1214
Praxis
Grundlagen und Behandlung

Fette runter mit Omega-3?

Volker Schmiedel

Summary

Immer wieder hört man, dass Omega-3-Fettsäuren die Blutfette senken. Doch was ist gesichert? Werden nur die Triglyzeride gesenkt oder auch das Cholesterin, und hier besonders das als schädlich angesehene LDL? Haben alle Omega-3-Fettsäuren diese Effekte oder gibt es Unterschiede zwischen den einzelnen Omega-3-Fettsäuren? In diesem Artikel soll die wissenschaftliche Datenlage hierzu gesichtet werden. Eine Kasuistik veranschaulicht darüber hinaus, wie die Risikoberechnung für Atherosklerose in der Praxis aussieht und wann Statine indiziert sind beziehungsweise wann eher nicht.



Publikationsverlauf

Artikel online veröffentlicht:
23. Mai 2023

© Karl F. Haug Verlag in Georg Thieme Verlag
KG

 
  • Literatur

  • 1 Backes J, Anzalone D, Hillemaπ D. et al The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemia. Lipids Health Dis 2016; 15 (01) 118
  • 2 Weintraub HS. Overview of prescription omega-3 fatty acid products for hypertriglyceridemia. Postgrad Med 2014; 126 (07) 7-18
  • 3 Choi HD, Chae SM. Comparison of efficacy and safety of combination therapy with statins and omega-3 fatty acids versus statin monotherapy in patients with dyslipidemia: A systematic review and meta-analysis. Medicine (Baltimore) 2018; 97 (50) e13593
  • 4 Natto ZS, Yaghmoor W, Alshaeri HK. et al Omega-3 fatty acids effects on inflammatory biomarkers and lipid profiles among diabetic and cardiovascular disease patients: A systematic review and meta-analysis. Sci Rep 2019; 9 (01) 18867
  • 5 Marston NA, Giugliano RP, Im KA. et al Association between triglyceride lowering and reduction of cardiovascular risk across multiple lipid-lowering therapeutic classes: A systematic review and meta-regression. Circulation 2019; 140 (16) 1308-1317
  • 6 Goh YK, Jumpsen JA, Ryan EA. et al Effect of omega-3 fatty acid on plasma lipids, cholesterol and lipoprotein fatty acid content in NIDDM patients. Diabetologia 1997; 40 (01) 45-52
  • 7 Wilkinson P, Leach C, Ah-Sing EE. Influence of alpha-linolenic acid and fish-oil on markers of cardiovascular risk in subjects with an atherogenic lipoprotein phenotype. Atherosclerosis 2005; 181 (01) 115-124
  • 8 Talebi S, Bagherniya M, Atkin SL. et al The beneficial effects of nutraceuticals and natural products on small dense LDL levels, LDL particle number and LDL particle size: A clinical review. Lipids Health Dis 2020; 19 (01) 66
  • 9 Elizabeth C, Leigh-Firbank EC, Minihane AM. et al Eicosapentaenoic acid and docosahexaenoic acid from fish oils: Differential associations with lipid responses. Br J Nutr 2002; 87 (05) 435-445
  • 10 Mahmoud Ebrahim M, Ghayour-Mobarhan M, Rezaiean S. et al Omega-3 fatty acid supplements improve the cardiovascular risk profile of subjects with metabolic syndrome, including markers of inflammation and auto-immunity. Acta Cardiol 2009; 64 (03) 321-327
  • 11 Green P, Fuchs J, Schoenfeld N. et al Effects of fish-oil ingestion on cardiovascular risk factors in hyperlipidemic subjects in Israel: A randomized, double-blind crossover study. Am J Clin Nutr 1990; 52 (06) 1118-1124
  • 12 Brown AJ, Roberts DC, Pritchard JE. et al A mixed Australian fish diet and fish-oil supplementation: Impact on the plasma lipid profile of healthy men. Am J Clin Nutr 1990; 52 (05) 825-833
  • 13 Nilsen DW, Albrektsen G, Landmark K. et al Effects of a high-dose concentrate of n-3 fatty acids or corn oil introduced early after an acute myocardial infarction on serum triacylglycerol and HDL cholesterol. Am J Clin Nut 2001; 74 (01) 50-56
  • 14 Kana Ide K, Masaya Koshizaka M, Tokuyama H. et al N-3 polyunsaturated fatty acids improve lipoprotein particle size and concentration in Japanese patients with type 2 diabetes and hypertriglyceridemia: A pilot study. Lipids Health Dis 2018; 17 (01) 51